

Temporary benefits added to the *Alberta Drug Benefit List (ADBL)*

Due to the unavailability of Ketorolac Tromethamine 30 mg/ml Injection (DIN 02239944), manufactured by Sandoz Canada Inc., Ketorolac Tromethamine 30 mg/ml Injection (DIN 02443376), manufactured by Juno Pharmaceuticals Corp., will be considered as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

As of **June 16, 2020**, all claims for Ketorolac Tromethamine 30 mg/ml Injection (DIN 02443376) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The ABCDPL is available online at <https://www.ab.bluecross.ca/providers/pharmacy-home.php>.

If this situation continues to be a long-term matter, then this product is subject to the usual review process by the Expert Committee on Drug Evaluation and Therapeutics and must be approved by the Minister of Health for addition to the *ADBL* to remain as a benefit.

Due to the unavailability of Methotrexate Sodium 25 mg/ml Injection (Unpreserved) (DIN 02182955), manufactured by Pfizer Canada ULC., and Methotrexate 25 mg/ml Injection (Unpreserved) (DIN 02099705), manufactured by Teva Canada Limited., Methotrexate Sodium (Unpreserved) 10 mg/ml Injection (DIN 02182947), manufactured by Pfizer Canada ULC., will be considered as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

As of **June 17, 2020**, all claims for Methotrexate Sodium (Unpreserved) 10 mg/ml Injection (DIN 02182947) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The ABCDPL is available online at <https://www.ab.bluecross.ca/providers/pharmacy-home.php>.

If this situation continues to be a long-term matter, then this product is subject to the usual review process by the Expert Committee on Drug Evaluation and Therapeutics and must be approved by the Minister of Health for addition to the *ADBL* to remain as a benefit.

Due to the unavailability of Methotrexate Sodium (Preserved) 25 mg/ml Injection (DIN 02182777), manufactured by Pfizer Canada ULC., and Methotrexate (Preserved) 25 mg/ml Injection USP (DIN 02398427), manufactured by Sandoz Canada Inc., Methotrexate Sodium 25 mg/ml Injection Syringe BP (DIN 02422204), manufactured by Pharmascience Inc., will be considered as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

As of **June 17, 2020**, all claims for Methotrexate 25 mg/ml Injection Syringe BP (DIN 02422204) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The ABCDPL is available online at <https://www.ab.bluecross.ca/providers/pharmacy-home.php>.

If this situation continues to be a long-term matter, then this product is subject to the usual review process by the Expert Committee on Drug Evaluation and Therapeutics and must be approved by the Minister of Health for addition to the *ADBL* to remain as a benefit.

Temporary benefit removed from the *Alberta Drug Benefit List (ADBL)*

... continued from previous page

Alberta Blue Cross has been advised by their respective manufacturers that the shortages for the following products have been resolved.

DIN	Product Description	Manufacturer
02365359	Apo-Candesartan 8 mg Tablet	Apotex Inc.
02388707	Candesartan 8 mg Tablet	Sivem Pharmaceuticals ULC
02388928	Candesartan 8 mg Tablet	Sanis Health Inc
02379279	Candesartan Cilexetil 8 mg Tablet	Accord Healthcare Inc
02386518	Jamp-Candesartan 8 mg Tablet	Jamp Pharma Corporation
02476916	Mint-Candesartan 8 mg Tablet	Mint Pharmaceuticals Inc
02391198	pms-Candesartan 8 mg Tablet	Pharmascience Inc
02326965	Sandoz Candesartan 8 mg Tablet	Sandoz Canada Inc

Due to the long-term nature of these shortages, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **July 20, 2020**.

CANDESARTAN CILEXETIL

8 MG TABLET

00002365359	APO-CANDESARTAN	APX	\$ 0.2281
00002445794	AURO-CANDESARTAN	AUR	\$ 0.2281
00002388707	CANDESARTAN	SIV	\$ 0.2281
00002388928	CANDESARTAN	SNS	\$ 0.2281
00002379279	CANDESARTAN CILEXETIL	AHI	\$ 0.2281
00002386518	JAMP-CANDESARTAN	JPC	\$ 0.2281
00002476916	MINT-CANDESARTAN	MPI	\$ 0.2281
00002391198	PMS-CANDESARTAN	PMS	\$ 0.2281
00002380692	RAN-CANDESARTAN	RAN	\$ 0.2281
00002326965	SANDOZ CANDESARTAN	SDZ	\$ 0.2281
00002366312	TEVA-CANDESARTAN	TEV	\$ 0.2281
00002239091	ATACAND	AZC	\$ 1.2847

When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

780-498-8370 (Edmonton and area) • 403-294-4041 (Calgary and area) • 1-800-361-9632 (toll free)

FAX 780-498-8406 (Edmonton and area) • FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefits and supplemental claiming information to assist with the submission of your direct bill drug claims. Visit ab.bluecross.ca/providers/pharmacy-home.php

